Quantcast

Latest Ustekinumab Stories

2014-08-21 08:28:17

INDIANAPOLIS, Aug. 21, 2014 /PRNewswire/ -- -- Ixekizumab met all primary and key secondary objectives across three pivotal studies of 3,866 patients, the largest Phase 3 moderate-to-severe plaque psoriasis program to date -- Ixekizumab was superior to etanercept on all measures of skin clearance in both active comparator studies -- Lilly plans regulatory submissions for ixekizumab in 1(st) half of 2015 Eli Lilly and Company's (NYSE: LLY)...

2014-08-05 08:35:59

LONDON, Aug. 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growthhttp://www.reportbuyer.com/pharma_healthcare/treatments/systemic_psoriasis_therapeutics_major_developed_markets_2020_continued_uptake_biologics_novel_pipeline_drugs_drive_growth.htmlSystemic Psoriasis Therapeutics in Major Developed Markets to 2020 -...

2014-07-24 16:24:29

Emerging Therapies, Especially IL-17 Inhibitors, Have Potential Relative to Current Therapies in Improving Psoriatic Plaques, According to Findings from Decision Resources Group BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, according to surveyed U.S. and EU5 dermatologists, short-term and long-term effects on psoriatic plaque clearance are two of the attributes that most strongly influence their prescribing decisions in moderate to severe psoriasis....

2014-07-09 16:28:56

- Results of two Phase III psoriasis studies show secukinumab, the first psoriasis IL-17A inhibitor filed with regulatory bodies, met all co-primary and key secondary endpoints[1] EAST HANOVER, N.J., July 9, 2014 /PRNewswire/ -- Novartis today announced that The New England Journal of Medicine (NEJM) published the results from two pivotal Phase III studies evaluating the interleukin-17A (IL-17A) inhibitor secukinumab (AIN457). Secukinumab met all primary and key secondary...

2014-05-09 16:24:31

Study Evaluating Novel Investigational IL-17 Receptor Antibody Meets All Primary and Secondary Endpoints THOUSAND OAKS, Calif. and LONDON, May 9, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and AstraZeneca today announced that the Phase 3 AMAGINE-1(TM) study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. Brodalumab is the only investigational treatment in development that binds to the...

2014-05-05 12:28:40

European Dermatologists Indicate that Fewer than Half of Their Severe Patients are being Treated with a Biologic, According to Findings from Decision Resources Group BURLINGTON, Mass., May 5, 2014 /PRNewswire/ -- Decision Resources Group finds that the use of biologics for the treatment of psoriasis among dermatologists has remained relatively flat since 2011 in the major European markets (France, Germany, Italy, Spain and the United Kingdom), with less than half of severe patients being...

2014-03-24 08:28:42

Results from Phase 2b X-PLORE Study through Week 40 Report Efficacy of Guselkumab across Multiple Dosing Regimens and Compared with Adalimumab DENVER, March 24, 2014 /PRNewswire/ -- New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology (AAD) showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared or minimal at week 16, the...

2014-02-06 23:24:53

MarketResearchReports.Biz announces addition of new report “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description” to its database. Visit: http://www.marketresearchreports.biz/analysis/186872 Albany, NY (PRWEB) February 06, 2014 Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description Research...

2013-11-12 23:25:17

Reportbuyer.com just published a new market research report: Psoriasis Treatment: World Drug Market 2013-2023. London (PRWEB) November 12, 2013 Report Details Psoriasis drugs - this new study shows you R&D, opportunities, and potential revenues What's the future of treating psoriasis? Visiongain's new report gives you revenue predictions from 2013, helping you stay ahead. There you see financial results, R&D trends, opportunities, and potential revenues. Avoid falling...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related